Related Experiment Video
Updated: Apr 20, 2026
Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Published on: July 17, 2016
Statin treatment affects cytokine release and phagocytic activity in primary cultured microglia through two separable
Matthew A Churchward1,2, Kathryn G Todd3,4,5
1Neurochemical Research Unit, University of Alberta Faculty of Medicine, Edmonton, AB, Canada, T6G 2R3. churchward@ualberta.ca.
Background:
As the primary immune cells of the central nervous system, microglia contribute to development, homeostasis, and plasticity of the central nervous system, in addition to their well characterized roles in the foreign body and inflammatory responses. Increasingly, inappropriate activation of microglia is being reported as a component of inflammation in neurodegenerative and neuropsychiatric disorders. The statin class of cholesterol-lowering drugs have been observed to have anti-inflammatory and protective effects in both neurodegenerative diseases and ischemic stroke, and are suggested to act by attenuating microglial activity.
Results:
We sought to investigate the effects of simvastatin treatment on the secretory profile and phagocytic activity of primary cultured rat microglia, and to dissect the mechanism of action of simvastatin on microglial activity. Simvastatin treatment altered the release of cytokines and trophic factors from microglia, including interleukin-1-β, tumour necrosis factor-α, and brain derived neurotrophic factor in a cholesterol-dependent manner. Conversely, simvastatin inhibited phagocytosis in microglia in a cholesterol-independent manner.
Conclusions:
The disparity in cholesterol dependence of cytokine release and phagocytosis suggests the two effects occur through distinct molecular mechanisms. These two pathways may provide an opportunity for further refinement of pharmacotherapies for neuroinflammatory, neurodegenerative, and neuropsychiatric disorders.
Insights
Simvastatin affects microglia by altering cytokine release in a cholesterol-dependent way and inhibiting phagocytosis independently of cholesterol, suggesting distinct mechanisms for treating neuroinflammation.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Microglia are key immune cells in the central nervous system, involved in homeostasis and neuroinflammation.
- Dysregulated microglial activation is implicated in neurodegenerative and neuropsychiatric disorders.
- Statins, cholesterol-lowering drugs, show neuroprotective effects by potentially modulating microglial activity.
Purpose of the Study:
- To investigate simvastatin's impact on primary rat microglia's secretory profile and phagocytic activity.
- To elucidate the underlying mechanisms of simvastatin's action on microglial functions.
Main Methods:
- Primary rat microglia cultures were treated with simvastatin.
- Secretory profiles (cytokines, trophic factors) and phagocytic activity were assessed.
- Cholesterol dependence of simvastatin's effects was analyzed.
Main Results:
- Simvastatin altered the release of cytokines (e.g., IL-1β, TNF-α) and BDNF in a cholesterol-dependent manner.
- Simvastatin inhibited microglial phagocytosis through a cholesterol-independent pathway.
- Distinct mechanisms underlie simvastatin's effects on cytokine release versus phagocytosis.
Conclusions:
- The differential cholesterol dependence of simvastatin's effects on microglia highlights distinct molecular pathways.
- These findings suggest potential for targeted therapies in neuroinflammatory, neurodegenerative, and neuropsychiatric conditions.
- Further research into these pathways could refine pharmacotherapies for brain disorders.
